ClinicalTrials.gg
CompletedNCT03629522EffOndUpdated Aug 14, 2018

Effects of Ondansetron on Hemodynamics in Cesarean Section Under Spinal Anesthesia

A Phase 4 interventional study of Ondansetron 8Mg/4mL Injection in Ondansetron, Cesarean Section and Spinal Anesthesia, sponsored by University Hospital, Mahdia. Completed at 2 sites in Tunisia. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by University Hospital, Mahdia · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2017, registered Apr 2018).
Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

BACKGROUND:

Spinal anesthesia (SA) induced maternal hypotension is the most frequent and troublesome complication in cesarean section (CS), compromising both maternal and neonatal well-being. Many strategies have been used to prevent its occurrence but no single technique has been confirmed to be completely effective. the investigators hypothesized that ondansetron, a serotonin-receptor-antagonist, could have beneficial effects on maternal hemodynamics during CS under SA.

METHODS:

In this prospective double-blind placebo-controlled study, one hundred healthy parturients were randomized to receive either 8 mg of intravenous ondansetron (group O) or the same volume of saline (group S), 5 minutes prior to the induction of SA. All women received a coloading volume of 500 ml of saline. Maternal hemodynamics: blood pressure, heart rate and cardiac output (CO) were measured with a non-invasive device based on pulse wave transit time: the esCCO device Nihon Kohden hemodynamic monitor. Ephedrine was administered to treat hypotension (systolic blood pressure less than 80% of baseline).

Read the detailed description
  1. Type of the study:

    After institutional ethical committee approval, we conducted a prospective double-blind, placebo-controlled, randomized study, at the department of anesthesiology of the Mahdia's university hospital, from August to November 2017.

  2. Inclusion criteria:

    Parturients eligible for the present study are women who:

    are scheduled for elective cesarean section under spinal anesthesia. aged between 20 to 40 years. are with an American Society of Anesthesiologist (ASA) physical status of I-II are with a normal liver and renal function and fetal screening, and with no medical history of heart disease.

    are with a single fetus.

  3. Protocol description:

3.1. Pre-operative time: A pre-anesthetic consultation, carried out at least 48 hours before the surgical procedure, made it possible to define eligible women for our study, to inform the parturients about the nature and the progress of the protocol and to collect their consent. Women were fasted for 6 hours before surgery and did not receive any premedication. In the morning of the intervention, a preoperative visit allowed us to check the application of instructions and the absence of intercurrent event.

3.2. per-operative time:

Randomization was performed at the entrance to the operating room after verification of the inclusion and exclusion criteria. All participants were randomly assigned to one of two groups according to a randomization table.

In the operating room, baseline values of noninvasive blood pressure (BP), electrocardiogram (ECG), and pulse oximetry (SPO2) were recorded using a Nihon Kohden monitor which also allowed a continuous non-invasive estimation of cardiac output (esCCO), based on pulse wave transit time (PWTT) which is automatically computed from pulse Oximetry waveform and electrocardiogram signals. After inputting the date of birth, sex, weight and height, the monitor was calibrated by the heart rate, pulse pressure, and PWTT.

Peripheral venous access was secured with an 18-gauge canula. An anesthesia nurse ; not included in the analysis ;verified the allocation and prepared the appropriate dose of Ondansetron (8 mg) with 0.9% saline solution to a total volume of 10 ml or a placebo of 0.9% saline solution10 ml. The syringes had no identifying markers indicating group allocation. The nurse injected the contents of the syringe intravenously over 60 s, 5 min before the lumbar puncture was performed. The anesthetist caring for the woman was blinded to group allocation.

Spinal anesthesia was induced in the sitting position at the L3-4 or L4-5 interspace, with a 25-gauge spinal needle pencil point. We administered 10 mg of 0.5% hyperbaric Bupivacaine, with 5ɤof Sufentanil and 100ɤof morphine. After injection, patients were immediately placed supine with 15 degrees left tilt. All women were rapidly coloaded with 500 ml of 0.9% saline solution.

Hemodynamic data were recorded at 2-min interval in the first 15-min and then every 5-min until the end of the procedure.

Sensory block height level was checked by assessing the perception of coldness using an alcohol swab, and motor block using Bromage scale.

Supplemental oxygen was administered via nasal canula at 2L/min. Maintenance fluids (10 ml/kg in the first one hour and 5ml/kg in the subsequent hours) were given at room temperature. Oxytocin was given following delivery of the fetus (5 IU directly and 10 IU in 250 ml of Glucose solution 5%). Antibioprophylaxis using 2g of Cefazolin was administered intravenously, in case of allergy, we used Clindamycin.

Neonatal Apgar score was noted at 1 and 5min after delivery.

Hypotension was defined as a decrease in systolic blood pressure (SBP)> 25% of baseline, and severe hypotension was defined as SBP\< 80 mmHg. Treatment was initiated with intravenous Ephedrine 9 mg. More bolus of Ephedrine can be required.

Bradycardia, defined as a decrease in heart rate (HR) to less than 50 beats/min, was treated with intravenous atropine 0.5 mg.

Tachycardia was defined as HR >120 beats/min. Low flow was defined as a decrease in cardiac output (CO) > 15% from baseline.

3.3. Post-operative time:

After surgery, all parturients were transferred to the post-intervention monitoring room.

Standard monitoring of all parturients systematically included heart rate (HR), non invasive blood pressure (NIBP), respiratory frequency (RR), uterine globe tonus, bleeding, diuresis and temperature.

A glucose solution 5 % infusion enriched with electrolytes and comprising 20 IU of Oxytocin was instituted at a rate of 2 liters to 3l/24 h depending on the weight of the parturient.

The protocol of postoperative analgesia is ensured by the administration of Paracetamol in slow intravenous infusion at the dose of 1gevery 6 hours and Nefopam at the dose of 20 mg in slow infusion of 30 min every 8 hours. The postoperative prescription included also for all parturients Enoxaparin-based thrombophylaxis for 7 days.

02

Conditions studied

  • Ondansetron
  • Cesarean Section
  • Spinal Anesthesia
  • Hemodynamics
03

In context

Lead sponsor

University Hospital, Mahdia is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parturients eligible for the present study are women who:

  • are scheduled for elective cesarean section under spinal anesthesia
  • aged between 20 to 40 years
  • are with an (ASA) physical status of I-II
  • are with a normal liver and renal function and fetal screening, and with no medical history of heart disease.
  • are with a single fetus.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate.
  • to spinal anesthesia
  • Age \<20 or >40 years.
  • Obesity ( (BMI) at term >35 kg/m2).
  • History of to study's drugs.
  • History of long syndrome
  • Hypertensive disorders of pregnancy.
  • Women receiving selective serotonin reuptake inhibitors or migraine medications.
  • Urgent cesarean section.
  • Multiple pregnancies.
  • Failure of spinal anesthesia.
  • Conversion to general anesthesia.
  • The occurrence of an anesthetic or surgical complication.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    ondansetron group

    Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia

    Drug: Ondansetron 8Mg/4mL Injection

  • Placebo comparator
    control group

    administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia

    Drug: Ondansetron 8Mg/4mL Injection

Interventions

  • DrugOndansetron 8Mg/4mL Injection

    Drug page: Ondansetron

    investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.

    Also known as: OD-C/S

06

What researchers measure

Primary outcomes

  1. hypotension

    decrease of systolic blood pressue with more than 25% from baseline values

    Time frame: 5 min after spinal anesthésia

Secondary outcomes

  1. escco

    decrease of cardiac output (contious non invasive estimation of cardiac output based on pulse wave transit time) with more than 15% from baseline values

    Time frame: 5 min after spinal anesthésia

  2. ephedrine consumption

    ephedrine dose used in perioperative time

    Time frame: during 2 hours of anesthetic time

07

Study locations

2 sites
  • Mahdia University Hospital
    Mahdia, 5100, Tunisia
  • Ministry of Health
    Tunis, 1002, Tunisia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03629522
Lead sponsor
University Hospital, Mahdia
Responsible party
Majdoub Ali MD (clinical professor, University Hospital, Mahdia) — Principal investigator
First posted
Aug 14, 2018
Start date
Aug 1, 2017
Primary completion
Nov 30, 2017
Completion
Dec 30, 2017
Last update
Aug 14, 2018

Study contacts

bechir haddad, professor
study director · tunisian Ministry of Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ondansetron

Start the discussion